

INTERRELATIONS OF VITAMIN B₁₂ AND FOLIC ACID METABOLISM: FOLIC ACID CLEARANCE STUDIES *

BY VICTOR HERBERT AND RALPH ZALUSKY

(From the Thorndike Memorial Laboratory and Second and Fourth (Harvard) Medical Services, Boston City Hospital, and the Department of Medicine, Harvard Medical School, Boston, Mass.)

(Submitted for publication December 18, 1961; accepted January 22, 1962)

The studies of many investigators have led to a unified concept of the megaloblastic anemias as a single morphologic entity due to defective nucleoprotein synthesis from various causes. The vast majority of patients with megaloblastic anemia have been found to have deficiency of vitamin B₁₂, of folic acid, or of both vitamins. For this reason, the possible interrelations of these two vitamins have long piqued the curiosity of investigators (1, 2).

Orally administered or injected pteroylglutamic acid (PGA) (folic acid) has been reported to disappear rapidly into the tissues of vitamin B₁₂-deficient patients, as manifested by rapid disappearance of *Streptococcus faecalis* activity from serum and urine (3-6).

The purpose of the present investigation was to determine whether the rapid disappearance of folic acid activity for *S. faecalis* from the serum of subjects with pernicious anemia reflects tissue depletion of folic acid, as believed by prior investigators, or instead indicates inadequate utilization of folic acid due to vitamin B₁₂ deficiency. Prior results of part of these studies (7-10) suggest that the latter is the case. Incidental to these observations, the effect of intravenously administered PGA on serum vitamin B₁₂ and on erythrocyte folic acid activity was determined.

The studies here presented elaborate on our preliminary reports (7-10), indicating that folic acid activity "piles up" in human serum in the presence of vitamin B₁₂ deficiency. The accumulation of this folic acid activity (probably N⁵-methyl-tetrahydrofolic acid) provides direct evidence of deranged folic acid metabolism due to vitamin B₁₂ deficiency. This folic acid-vitamin B₁₂ interrelationship may explain much of the confu-

sion in therapy of pernicious anemia, as well as the fact that the anemias of vitamin B₁₂ and folic acid deficiencies are hematologically identical.

MATERIALS AND METHODS

*Synthetic pteroylglutamic acid*¹ was diluted with saline to a concentration of 1 mg per ml. The concentration was proven by microbiologic assay with both *S. faecalis* and *Lactobacillus casei*, and the solution was stored at 4° C in sterile light-tight bottles.

Procedure. The subjects of the investigation were given 15 µg of PGA per kg of body weight by rapid intravenous injection (5). Blood samples were obtained at zero time (immediately before) and at 3, 8, 15, 30, 60, 120, 240, and 1,440 minutes (24 hours) after the injection. Serum samples were obtained in plain Vacutainers² and whole blood samples in heparinized Vacutainers.

Estimations of folic acid activity in serum and erythrocytes. These were carried out by microbiologic assay with *L. casei* and *S. faecalis* as previously reported (8), using both the "standard method" (150 mg per 100 ml ascorbate) and the "aseptic addition method" (1 g per 100 ml ascorbate) (8). The latter method has the advantages of halving the manipulations involved in preparing an assay, and allowing assay of 0.1 ml of serum. (Strict asepsis is not necessary, since *L. casei* grows so rapidly that we have never observed growth of a contaminant.)

In our laboratory, serum *L. casei* values of < 3 mµg per ml are considered indicative of folic acid deficiency; values of 3 to 4.9 mµg per ml are strongly suggestive of folic acid deficiency; values of 5 to 6.9 mµg per ml are diagnostically indeterminate; values of 7 to 15.9 mµg per ml are normal; values of 16 to 24.9 are suggestively elevated and may indicate folic acid ingestion by normal subjects; and values > 25 mµg per ml have never been found in normal subjects unless they were ingesting vitamin tablets containing folic acid.

The folic acid activity of 1 ml of erythrocytes was determined using the same methodology (8) previously applied to serum. "Reticulocyte-rich" and "reticulocyte-

* Aided in part by research grants from the National Institutes of Health, USPHS (A-795 (C4)) and (A-3853), and the National Vitamin Foundation.

¹ Folic acid-Folvite, a solution of pteroylglutamic acid, 15 mg per ml, generously provided by Drs. T. H. Jukes and E. L. R. Stokstad of Lederle Laboratories, Pearl River, N. Y.

² Becton, Dickinson & Co., Rutherford, N. J.

poor" erythrocytes were prepared as follows. On the eighth day of therapy with 30 μg of vitamin B_{12} daily, 100 ml of blood was obtained from Subject 5 and centrifuged. The buffy coat was discarded and the red cells were thrice washed in 0.9 per cent NaCl, discarding the top-most layer of "residual buffy coat." The middle half of the erythrocyte layer was again centrifuged to yield a "reticulocyte-rich" top layer (26 per cent reticulocytes) and a "reticulocyte-poor" bottom layer (6 per cent reticulocytes); 0.2-ml aliquots of erythrocytes were then assayed by our "standard method" (8).

Serum vitamin B_{12} levels. These were determined using *Euglena gracilis*, var. *bacillaris*, by the method of Lear, Harris, Castle and Fleming (11), with various trivial modifications. In our laboratory, values $< 120 \mu\text{g}$ per ml are low; values of 121 to 200 μg per ml are indeterminate; values of 200 to 900 μg per ml are normal; and values $> 900 \mu\text{g}$ per ml are high.

Erythrocyte vitamin B_{12} levels. The methodology of Spray (12) for extracting vitamin B_{12} from serum was applied to extracting the vitamin from erythrocytes. One ml of erythrocytes, 1 ml of 0.4 N acetate buffer (pH 4.5), 0.4 ml of 0.1 per cent NaCN, and 17.6 ml distilled water were autoclaved together at 118° C for 15 minutes. After cooling and centrifugation, the supernate was assayed as if it were serum (vide supra).

In other studies (13), this extraction procedure was

shown to remove approximately 81 per cent of the total vitamin B_{12} radioactivity from 1 g of liver obtained at sacrifice of a baby pig who had been given daily injections of radioactive vitamin B_{12} for almost 2 months. After the final injection and before sacrifice, there was a rest period of 5 days to allow equilibration of the last injections of radioactive vitamin B_{12} with tissue vitamin B_{12} . (The extract contained 81 per cent and the precipitate contained 19 per cent of the total liver radioactivity.) A similar efficiency of extraction is assumed for erythrocytes, although we are not aware of studies using a radioactive marker to demonstrate this probability.

Estimation of formiminoglutamic aciduria. After ingestion of 20 g of L-histidine, urine was collected for 12 hours in a bottle containing 2 ml of concentrated HCl, and the quantity of formiminoglutamic acid (FIGLU) was estimated by a modification (14) of the electrophoretic method of Knowles, Pranker and Westall (15).

Clinical and laboratory criteria for diagnosis (2). Vitamin B_{12} deficiency: hematologic morphologic abnormalities in the peripheral blood (macroovalocytes and hypersegmented polymorphonuclear leukocytes) and bone marrow (megaloblasts and giant metamyelocytes); serum vitamin B_{12} level $< 100 \mu\text{g}$ per ml.

Folic acid deficiency: same morphologic criteria as for vitamin B_{12} deficiency; serum folic acid activity for *L. casei* $< 3 \mu\text{g}$ per ml (except in the presence of concomi-




FIG. 1. FOLIC ACID CLEARANCE IN NORMAL SUBJECTS.

TABLE I
Pteroylglutamic acid disappearance studies*

Sub-jects	PGA dose mg	Het	FIGLU mg/12 hrs	Serum B ₁₂ µg/ml	Serum folic acid activity (µg/ml)																		
					<i>S. faecalis</i>						<i>L. casei</i>												
					0 min	3 min	8 min	15 min	30 min	1 hr	2 hrs	4 hrs	24 hrs	0 min	3 min	8 min	15 min	30 min	1 hr	2 hrs	4 hrs	24 hrs	
Normal																							
1	1.02	40.0		277	<3	>100	90	74	35	15	7.2	3.4	<3	7.7	>300	>300	>100	60	43	28	16	8.6	
2	1.19	40.0		560	<1	>100	98	77	47	26	14	5.8	<3	6.5	>300	>100	>100	57	27	20	15	7.0	
3	0.99	41.0		472	<1	>100	85	38	28	10.2	3.6	1.5	<1	8.4	>100	>100	>100	57	33	22	15	7.2	
Megaloblastic anemia due to vitamin B ₁₂ deficiency																							
4	0.82	13.0	939	28	1.8	80	80	4.3	3.0	2.5	3	3.1	3.2	8.5	92	>240	>240	64	31	23	28	18	
4a	0.82	33.2	15	59	<1	87	19	4.1	<1	<1.1	<3	<1	3	7.2	97	50	20	19	16	17	16	18	
5	1.33	13.8	86	18	<1	58	9.9	3.2	1.3	<1	<1	<1	1.3	35	>300	240	128	20.5	19.5	19	24	12.5	
5a	1.33	33		692	3.7	>300	240	60	18	<1	5	3.8	3.8	7	>300	212	58	33	26	23	47	33	
6	1.0	23.0		73	<3	82	14	4.6	<3.4	<3	<3	<3	16	19	>300	40	89	36	30	41	41	8.4	
6a	1.0	35.5			<1	155	55	16	3.8	<1	<1	<1	7.4	10	>300	>240	64	31	23	28	28	41	
Megaloblastic anemia due to folic acid deficiency																							
7	0.436	25		371	2.4	36	15.5	6	1.5	1.5	2.4	<3	2.7	1.3	40	16.5	8.8	2.9	3.2	2.3	3.4	3.4	
8	0.61	30		>3,014	<3	74	19	5.4	<3	<3	<3	<3	<3	2.3	88	32	9.6	4.7	4.1	3.7	3.9	3.9	
9	0.75	24.2		>1,352	<1.8	71	22	5.1	<1.8	1.0	1.8	1.8	1.8	1.5	90	28	7.7	2.9	2.8	3.4	3.3	1.5	
Vitamin B ₁₂ deficiency without overt anemia																							
10	1.125	45		68	<1	140	78	44	18.5	7.6	1.6	<1	<1	21	250	120	96	80	61	55	30	12	
Megaloblastic anemia due to deficiencies of both vitamin B ₁₂ and folic acid																							
11	0.612	25		56	1.9	91	20	2.7	1.6	1.1	1.2	1.5	1.8	1.3	160	21	4.3	2	3.3	4.3	3.5	2.8	
12	0.75	14		59	<1	9.4	1.1	<1	<1	<1	<1	<1	<1	4	29	14	7.8	7	7.4	7.9	7.2	6.9	

* PGA = pteroylglutamic acid; FIGLU = formiminoglutamic acid.

tant vitamin B₁₂ deficiency, which may raise the serum folic acid activity above 3 mμg per ml).

Pernicious anemia: anemia due to vitamin B₁₂ deficiency caused by idiopathic lack of adequate intrinsic factor secretion.

RESULTS

Normal subjects. In three normal subjects, folic acid activity for both *L. casei* and *S. faecalis* remained elevated for at least 4 hours after intravenous injection of PGA, returning to baseline levels some time between 4 and 24 hours after the intravenous dose (Figure 1 and Table I, Subjects 1-3).

Megaloblastic anemia due to folic acid deficiency. In three such subjects, within 30 minutes after the intravenous injection of PGA, an acute rise in serum folic acid activity occurred, *S. faecalis* activity had fallen below 2 mμg per ml, and *L. casei* activity had fallen to below 5 mμg per ml (Figure 2 and Table I, Subjects 7-9).

Megaloblastic anemia due to vitamin B₁₂ deficiency. In three such subjects, serum folic acid activity for *S. faecalis* fell to 3 or less mμg per ml of serum within 30 minutes after the acute rise

produced by the intravenous PGA injection (Figure 3). However, serum folic acid activity for *L. casei* remained elevated for at least 4 hours after intravenous PGA injection (Figure 3 and Table I, Subjects 4-6).

After the folic acid clearance study, Subject 4, who has been reported elsewhere in connection with his high FIGLU excretion (16), was treated with 5 μg of vitamin B₁₂ daily for 7 days, inducing a 51.9 per cent reticulocytosis and hematologic improvement. He was then allowed to relapse and, 2 months after the first clearance study (Table I, Subject 4), a second one (Table I, Subject 4a) was performed; the results were similar.

Immediately after the intramuscular administration of 30 μg of vitamin B₁₂ daily for 18 days, Subject 5 cleared folic acid activity for both organisms at a rate which was relatively normal (Table I, Subject 5a) compared with these clearances prior to therapy (Table I, Subject 5).

Immediately after the administration of 1 mg of vitamin B₁₂ intramuscularly daily for 8 days, Sub-




FIG. 2. FOLIC ACID CLEARANCE IN FOLIC ACID-DEFICIENT SUBJECTS.




FIG. 3. FOLIC ACID CLEARANCE IN VITAMIN B₁₂-DEFICIENT SUBJECTS.

ject 6³ cleared folic acid activity for *S. faecalis* somewhat more rapidly than did normal subjects (Table I, Subject 6a), and cleared folic acid activity for *L. casei* at a rate (Table I, Subject 6a) similar to that prior to therapy (Table I, Subject 6).

Vitamin B₁₂ deficiency without overt anemia. An 80 year old white male was studied for 9 months, after routine evaluation prior to cholecystectomy led to discovery of macroovalocytes and hypersegmentation of polymorphonuclear leukocytes in his peripheral blood. His serum vitamin B₁₂ level was low but no therapy was given, since it was desired to determine how long it would take for a fall in hematocrit. The disappearance of *S. faecalis* activity from his serum after intravenous PGA was normal, but the disappearance of *L. casei* activity appeared suggestively prolonged (Table I, Subject 10; note 2- and 4-hour levels).

³ This patient of the Peter Bent Brigham Hospital was made available for study by Drs. Alan Keitt and Stanley Yachnin.

Megaloblastic anemia due to deficiencies of both vitamin B₁₂ and folic acid. Two such patients were studied. Subject 11 had idiopathic steatorrhea (nontropical sprue); Subject 12 had pernicious anemia with associated folic acid deficiency (presumably due to protracted anorexia). Subject 11, who had more marked folic acid deficiency, rapidly cleared folic acid activity for both microorganisms from his blood stream. Subject 12, with less marked folic acid deficiency, cleared

TABLE II

Serum folic acid activity for L. casei of 100 consecutive subjects with vitamin B₁₂ deficiency characterized by megaloblastic anemia and a serum vitamin B₁₂ level < 100 µg per ml

No. of subjects	"Folic acid" µg/ml	Interpretation
9	0 to 2.9	FAD*
24	3 to 4.9	Strongly suggestive of FAD
7	5 to 6.9	Diagnostically indeterminate
34	7 to 15.9	Normal
9	16 to 24.9	Diagnostically indeterminate
17	25 to 83 (Mean: 39)	High

* FAD = folic acid deficiency.

TABLE III
Serial serum vitamin B₁₂ levels after intravenous pteroylglutamic acid

Subjects	PGA dose	Hct	Serum "folic acid"	Serum vitamin B ₁₂ levels (μg/ml)									
				0 min	3 min	8 min	15 min	30 min	1 hr	2 hrs	4 hrs	24 hrs	
Controls	mg		mμg										
3	0.99	41	8.4	472	835	464	845	581	464	731	632	560	
Megaloblastic anemia due to vitamin B ₁₂ deficiency													
4	0.82	13	8.5	28	30		28	25	26	31	27	29	
4a*	0.82	33.2	7.2	51			44			62		57	
5	1.33	13.8	35	18	22	22	30	28	19	22	24	21	
5a†	1.33	33	7	440	357	416	485	365	307	419		325	
6	1.0	23	16	16	22	60	59	38	39	41			
Megaloblastic anemia due to folic acid deficiency													
7	0.436	25	1.3	371	301	321		292	359	304			
8	0.61	30	2.3	>3,200	>3,200		>3,200		>3,200				>3,200
Megaloblastic anemia due to deficiencies of both vitamin B ₁₂ and folic acid													
11	0.612	25	1.3	56	71		54	51			54	51	
12	0.75	14	4	59	57	56	49	51	42	55	51	52	

* Subject 4 in a second relapse (see text).

† Subject 5 after therapy with vitamin B₁₂.

TABLE IV
Erythrocyte folic acid activity after intravenous injection of pteroylglutamic acid

Subjects (controls)	PGA dose	Hct	<i>S. faecalis</i> (mμg/ml)										<i>L. casei</i> (mμg/ml)									
			0 min	3 min	8 min	15 min	30 min	1 hr	2 hrs	4 hrs	24 hrs	0 min	3 min	8 min	15 min	30 min	1 hr	2 hrs	4 hrs	24 hrs		
2	1.19	40	7.6	8.6	8.6	9	7.8	8.4	7.8	8.6	7.4	44	24	26	30	24	22	28	22	16.4		
3	0.99	41	5.6	8.2	8.0	7	7.2		8.2	7.2	16	33	43	39	38	27	23	25	14			

S. faecalis activity as rapidly as did subjects with severe folic acid deficiency. Her initial clearance of *L. casei* activity was rapid but then appeared to "plateau" at a level approximately 3 mμg per ml above baseline (Table I).

Baseline serum folic acid activity for *L. casei* of patients with untreated vitamin B₁₂ deficiency. Of 100 consecutive such subjects, none of whom were ingesting vitamin tablets, 17 had initial serum folic acid activity for *L. casei* of 25 mμg per ml or more (Table II). Minimal criteria for characterizing these patients as having vitamin B₁₂ deficiency were the presence of a megaloblastic anemia and of a serum vitamin B₁₂ level < 100 μg per ml.

Serial serum vitamin B₁₂ levels after intravenous PGA administration. These showed no significant pattern of increase or decrease (Table III).

Erythrocyte folic acid activity for *L. casei*. No significant measurable increase in erythrocyte folic acid activity followed the standard intravenous injection of PGA (Table IV), suggesting that the mature erythrocyte is relatively impermeable to folic acid.

Folic acid activity (and vitamin B₁₂ activity) was much higher in "reticulocyte-rich" than in "reticulocyte-poor" erythrocytes obtained during vitamin B₁₂ therapy for pernicious anemia (Table V), suggesting the relative permeability to folic acid and vitamin B₁₂ of young erythrocytes. [It has previously been observed (17) that there is an increased concentration of radioactive vitamin B₁₂ in the stroma protein of erythrocytes during active blood regeneration in anemia in dogs.] *L. casei* folic acid activity of leukocytes appears to be higher than that of erythrocytes (18).

Effect of specific therapy with vitamin B₁₂ on serum folic acid activity for *L. casei*. Table VI

TABLE V
Concentration of vitamin activity in reticulocytes

Subject 5 (day 8 of vitamin B ₁₂ therapy)	"Folic acid" Vitamin B ₁₂	
	mμg/ml	μg/ml
Serum	5.8	891
"Reticulocyte-rich" erythrocytes (26% reticulocytes)	273	2,004
"Reticulocyte-poor" erythrocytes (6% reticulocytes)	29	621

TABLE VI
Effect of vitamin B₁₂ therapy on serum folic acid activity for L. Cases

Subject	Before therapy		B ₁₂ therapy (i.m.)	Reticulocyte peak		Serum FAA* during hematologic response							
	Hct	Serum B ₁₂ μg/ml		Day†	%	Day†	0	1	2	3	4	5	6-10
13	15	23	1 × 9‡	18	6	7	6.8	7.8	7.8	8.4	8.4	13.3[6]§; 10.1[7]	
14	18.5	12.5	1 × 11	12.2	9	8.6	7.2	7.3	5.8	6.4	15.3	8.2[7]; 9[8]; 9.3[9]; 11.5[10]	12.5[13]
15	29	50	1 × 12	6.8	6	28.3						22.7[8]	12.6[21]
16	16.7	26	1 × 26	24.9	6	27 ¶						1[7]; 4.1[8]	21[13]; 15.3[28]
4	13	28	5 × 7	51.9	6	8.5			3.9			8.9[7]; 7.2[8]; 6.5[10]	5[11]; 8.9[26]
21	26	26	10 × 10	16.5	7	8.1	8	5.3	7.3	8.3			3.6[12]
17	25	20	30 × 7	15.1	7	12	5					5[6]; 5.8[7]	7[19]; 11[22]
5	13.8	18	30 × 20	40.7	5	35							
22	20	24	50 × 6	9.5	7	9.4	4.2	3.4	4.5	3.7			
20**	28	25	1,000 × 1			25			8				
23	24	33	1,000 × 5	15.5	5	9.8	3.6						
6	23	73	1,000 × 7	19	6	16	5		3.9		7.4[9]		7.4[13]
18	17	38	1,000 × 14	27.8	4	14.5							5[11]; 10.9[51]
19	13.2	42	1,000 × 23	21.2	6	10.4					5.1		

* FAA is folic acid activity for L. cases.

† Under day 0 appear the values before therapy; under days 1, 2, 3, etc., are those on days after therapy was begun.

‡ Second number indicates the number of days therapy was given.

§ Numbers in brackets indicate the day the value was determined.

|| Diagnosis: B₁₂ deficiency due to total gastrectomy. In all other subjects, the diagnosis was pernicious anemia (except in Subject 20).

¶ Values during first 24 hours: 26 (5 min); 24 (15 min); 22.3 (30 min); 24.5 (1 hr); 25 (2 hrs); 28.5 (3 hrs).

** Diagnosis: B₁₂ deficiency due to regional enteritis with resection of part of the ileum (patient of Dr. Matthew Block, University of Colorado Medical Center).

shows that serum folic acid activity falls slowly during specific therapy with daily doses of 1 μg of vitamin B₁₂, but may fall relatively sharply with larger doses (5 to 1,000 μg).

DISCUSSION

As previously reported by Chanarin, Mollin and Anderson (5), we found that the clearance of folic acid activity for *S. faecalis* from the serum, after injection of 15 μg of PGA per kg of body weight, was rapid in anemic subjects with folic acid deficiency and also in anemic subjects with severe vitamin B₁₂ deficiency. This was also noted in a vitamin B₁₂-deficient subject (Subject 6a) after 8 days of administration of 1 mg of vitamin B₁₂ intramuscularly daily, when his hematocrit was 35.5, as well as in a patient with pernicious anemia (Subject 4a) in early hematologic relapse, with a hematocrit of 33.2 per cent. Thus, rapid clearance of *S. faecalis* activity may also occur in subjects with moderate vitamin B₁₂ deficiency who are only slightly to moderately anemic. However, the clearance of *S. faecalis* activity from the serum of a patient (Subject 5a) with vitamin B₁₂ deficiency, after 18 days of therapy with 30 μg of vitamin B₁₂ intramuscularly daily, when the hematocrit was 33 per cent, was essentially normal.

Microbiologic assay with *L. casei* also revealed rapid disappearance of folic acid activity from the serum after intravenous injection of PGA in patients with folic acid deficiency. However, in patients with vitamin B₁₂ deficiency, serum *L. casei* activity did *not* disappear as fast. In fact, a "plateau phenomenon" may be present, manifested by a tendency for serum *L. casei* activity to remain elevated well above baseline at a fairly constant level for at least 0.5 to 2 hours after the intravenous injection of PGA.

In subjects with vitamin B₁₂ deficiency, the combination of rapid clearance of *S. faecalis* activity and slow clearance of *L. casei* activity suggests that in such subjects PGA (which is available to both *S. faecalis* and to *L. casei*) is rapidly converted, perhaps in the liver, to a form only available to *L. casei*. This *L. casei*-active form then appears to "pile up" in the serum, suggesting that vitamin B₁₂ is required for its utilization.

During the course of therapy with daily doses of 1 μg vitamin B₁₂, changes in serum folic acid

activity for *L. casei* appear to occur very slowly, as may changes in serum iron when folic acid deficiency is treated with 50 μg of pteroylglutamic acid daily (19). When larger daily doses (5 to 1,000 μg) of vitamin B₁₂ are used, serum folic acid activity for *L. casei* appears to fall much more sharply, and may reach levels below normal before rising again into the normal range. This drop in serum folic acid activity for *L. casei* may have a meaning similar to the drop in serum iron (2, 20) which occurs during vigorous specific therapy of megaloblastic anemias.

Of the original ten patients with pernicious anemia in whom serum folic acid activity for *L. casei* was measured, one had a value of 43 m μg per ml (21). This value was described in the original report as "high, but of unknown significance." In the present report, we are able to throw some light on the significance of that finding. In the present study, review of 100 consecutive patients with vitamin B₁₂ deficiency revealed that 17 had initial serum folic acid activity for *L. casei* of 25 m μg per ml or more, and nine had values of 16 to 24.9 m μg per ml (Table II), despite frequent protracted anorexia, which would be expected to lower such activity. Waters and Mollin (22) have also observed increased serum folic acid activity for *L. casei* in untreated Addisonian pernicious anemia. The majority of our 100 patients had pernicious anemia. Those with serum *L. casei* folic acid activity < 7 m μg per ml frequently had debilitating complications, which may have led to associated anorexia with inadequate ingestion of folic acid, such as chronic genitourinary tract infection, alcoholism, or marked neurologic disability due to past cerebrovascular accident. One patient also had lupus erythematosus. Serum folic acid activity < 7 m μg per ml was also frequent among the patients with vitamin B₁₂ deficiency who did not have pernicious anemia. These were mainly patients with gastrointestinal dysfunction due to structural or functional small bowel damage, which may result in malabsorption for folic acid, and included patients with partial small intestine resection, idiopathic steatorrhea, total or subtotal gastrectomy with subsequent malabsorption, and carcinoma with abdominal metastases. Although in presumably normal subjects values of 7 to 24 m μg per ml have been observed, values above 16 m μg per ml are infrequent. These find-

ings, like the PGA clearance studies, suggest a tendency of the *L. casei*-active form of folic acid activity to accumulate in the serum of subjects with vitamin B₁₂ deficiency, as does the finding of normal serum *L. casei* activity despite moderately protracted anorexia in many other patients with pernicious anemia (10).

In view of the tendency of *L. casei*-active folic acid activity to accumulate in the serum of subjects with vitamin B₁₂ deficiency, it is possible that a low normal value for such activity may be present in the serum of a vitamin B₁₂-deficient subject with folic acid stores inadequate to sustain normal hematopoiesis, just as a normal serum iron level may be present in patients with untreated megaloblastic anemia who do not have iron stores adequate to sustain normal hematopoiesis (2).

Recent studies (23) suggest that most of the *L. casei* activity in human serum is due to a material similar or identical to N⁵-methyl-tetrahydrofolic acid (N⁵-methyl THFA), the folic acid coenzyme active as an intermediate in methionine biosynthesis (24–29), which requires vitamin B₁₂ in order to act (25, 26, 30, 31). Table VII summarizes present knowledge concerning the folic acid activity for microorganisms of various folic acid analogues.

Earlier clinical investigation of patients with vitamin B₁₂ deficiency has also provided evidence suggesting that vitamin B₁₂ is required for normal folic acid metabolism: 1) While normally the liver folic acid stores appear to be mainly folinic acid-like material, in vitamin B₁₂ deficiency states the stores had appeared to be mainly folic acid (32, 33). However, more recent studies indicate that the bulk of normal liver stores may be N⁵-methyl THFA which is only active for *L. casei* (23, 28,

34, 35). It is evident that much of the data in the literature will have to be re-evaluated in the light of this recent work. In severely vitamin B₁₂-deficient sheep, grazing on land deficient in cobalt, liver folic and folinic acid activity for *L. casei* and *L. citrovorum*, respectively, plummet to very low levels (36). 2) After an oral test dose of PGA, less folinic acid appears in the urine of pernicious anemia patients than in the urine of normal subjects (37). In vitamin B₁₂-deficient subjects previously treated with folic acid, the injection of 1 mg of vitamin B₁₂ doubles the urinary folic acid activity excreted (38). 3) Whole blood folic acid activity for *S. faecalis* appears to be low in one-half of patients with pernicious anemia (39). 4) Large doses of folic acid will almost invariably induce at least temporary or partial hematologic remission in vitamin B₁₂-deficient subjects (40). Conversely, large quantities of vitamin B₁₂ will induce partial hematologic remission in subjects with folic acid deficiency (41). 5) Formiminoglutamic acid (FIGLU), an intermediate in the catabolism of histidine, found in the urine (sometimes only after an oral dose of histidine) in folic acid deficiency (42, 43), also appears in the urine of some vitamin B₁₂-deficient subjects, sometimes in very large quantities (2, 14, 16, 21, 40, 44, 45), and is generally present in large quantities in the urine of vitamin B₁₂-deficient rats (46) and chicks (47).

Figure 4 presents, in abbreviated diagrammatic form, a hypothetical explanation⁴ for the "piling up" of *L. casei* activity in serum and of FIGLU in urine in vitamin B₁₂ deficiency. In this system, vitamin B₁₂ acts as coenzyme and folic acid as substrate. If one considers the two agents to interact in this relationship, one has a facile explanation for the fact that a relatively small increase (to 400 µg) (48) above the approximate minimal daily requirement (50 µg) (19) for folic acid may produce hematologic response in pernicious anemia, whereas a much larger increase (to 100 to 500 µg) (41) above the approximate minimal daily requirement (0.1 µg) (49) for vitamin B₁₂ appears necessary to produce a hematologic response in folic acid deficiency. Figure 4 may also explain the apparent decrease in FIGLU excretion by folic acid-deficient subjects when treated with 500 µg of vitamin B₁₂ daily (41).

The finding that methionine decreases FIGLU

TABLE VII
Folic acid activity for microorganisms of various
folic acid analogues

	<i>Leuconostoc citrovorum</i>	<i>S. faecalis</i>	<i>L. casei</i>
Reduced pteroylmonoglutamates (except N ⁵ -methyl)	+	+	+
Pteroylglutamic acid Pteroyldiglutamates*	-	+	+
N ⁵ -methyl folate-H ₂ N ⁵ -methyl folate-H ₄ Pteroyltriglutamates*	-	-	+

* *S. faecalis* does not grow well on some diglutamates; *L. citrovorum* may grow on some reduced di- and triglutamates (51, 52, 63).





FIG. 4. HYPOTHETICAL EXPLANATION IN ABBREVIATED DIAGRAMMATIC FORM OF THE "PILING UP" OF *L. casei* ACTIVITY IN SERUM AND OF FIGLU IN URINE IN VITAMIN B₁₂ DEFICIENCY. THFA IS TETRAHYDROFOLIC ACID. THE DASHED LINE REPRESENTS THE REACTION BLOCKED BY LACK OF VITAMIN B₁₂.


excretion in vitamin B₁₂-deficient rats (46) and chicks (47) has been discussed in terms of its possible biochemical meaning by Noronha and Silverman (50). They noted that methionine administration to the vitamin B₁₂-deficient rat eliminated FIGLU excretion and changed the folate pattern of the liver from predominantly N⁵-methyl THFA to N⁵- and N¹⁰-formyl THFA. They concluded that methionine provides an acceptor, directly or indirectly, for the methyl group of N⁵-methyl THFA, thus releasing THFA for the metabolism of carbon 2 of histidine (the formimino carbon), which then appeared as the N¹⁰-formyl group of N¹⁰-formyl THFA. It is also possible, however, that providing methionine may spare the entire pathway involving N⁵-methyl THFA, allowing greater production of THFA via other (unblocked) pathways. This could occur if, by negative feedback, there was suppression of the activity or synthesis of an enzyme required for the production of the metabolically blocked N⁵-methyl THFA.

As Figure 4 indicates, the increase in both serum *L. casei* activity and urine FIGLU may be



FA = FOLIC ACID (PTEROYLGLUTAMIC ACID) (F)
 DHFA = DIHYDROFOLIC ACID (FH₂)
 THFA = TETRAHYDROFOLIC ACID (FH₄)
 AICAR = AMINOIMIDAZOLECARBOXAMIDE RIBOTIDE

FIG. 5. INTERRELATIONS OF FOLATE COENZYMES, WITH REACTIONS DEPENDENT ON VITAMIN B₁₂ INDICATED.



BROKEN LINES OUTLINE THE BASIC 1-CARBON ACCEPTOR (5,6,7,8-TETRAHYDROFOLIC ACID) (THFA) (FH₄), AND THE VARIOUS 1-CARBON-DONATING COENZYMES DERIVED FROM IT.

FIG. 6. STRUCTURE OF PTEROYLGLUTAMIC (FOLIC) ACID AND VARIOUS FOLATE COENZYMES.

due to "piling up" of these substrates, whose utilization is blocked by lack of vitamin B₁₂. The "piling up" of N⁵-methyl THFA reduces the amount of folic acid available to travel via other metabolic pathways. Thus, this one "metabolic trap" could conceivably produce a generalized slowdown in all 1-carbon transfers. This may explain much of the apparent folic acid deficiency in many patients with vitamin B₁₂ deficiency.

Figure 5 presents the interrelations of the folate coenzymes in a more detailed context (23, 25, 26, 29, 51-56), which indicates the possible alternate pathways to THFA, whose variable activity may explain why FIGLU "piles up" in only a third (16, 45) of patients with pernicious anemia. Since N⁵-methyl THFA may be both the main circulating (23) and the main storage (liver) (23, 28, 34, 35) folate form in normal man, it is possible that this form of folic acid may play an even larger role in human metabolism than present studies suggest.

Figure 6 depicts the structure of pteroylglutamic (folic) acid, with the various folate coenzymes superimposed thereon. Note the close resemblance of the 5-membered ring of N⁵⁻¹⁰-methenyl THFA to the hydantoin ring of diphenylhydantoin (Dilantin, Phenytoin). Although prior work using *S. faecalis* led to the belief that "Folic acid tests have not indicated a deficiency, but rather a failure to utilize normal serum levels" (57), we found low folate activity for *L. casei* in the serum of 11 patients who had been receiving anticonvulsant therapy for periods in excess of 6 months (58). One may speculate that the folic acid-responsive megaloblastic anemia which sometimes occurs in such patients (2, 57, 59-62) may be due to weak competitive inhibition by anticonvulsants of the conversion of N⁵⁻¹⁰-methenyl THFA to N⁵-methyl THFA, possibly at the level of absorption of food folates. Competitive inhibition of the 6-membered pyrimidine ring of folic acid, as suggested by Girdwood (62), may explain the megaloblastic anemia

infrequently associated with anticonvulsants other than Dilantin.

These studies support the possibility that the megaloblastic anemia which follows vitamin B₁₂ deprivation may be partly the result of secondarily deranged folic acid metabolism. This may, in large measure, explain why the hematologic picture is the same in vitamin B₁₂ deficiency as it is in folic acid deficiency. Much of this hematologic similarity may also be due to the fact that lack of either folic acid or vitamin B₁₂ reduces thymidylate synthesis, as indicated in Figure 5 (51-56).

SUMMARY

In slightly to severely anemic vitamin B₁₂-deficient subjects, after the intravenous injection of 15 μ g pteroylglutamic acid (PGA) per kg of body weight, folic acid activity for *S. faecalis* disappears rapidly but activity for *L. casei* disappears slowly from the serum.

Markedly elevated serum folic acid activity for *L. casei* (25 or more m μ g per ml) was observed in 17 of 100 consecutive subjects with vitamin B₁₂ deficiency.

During specific therapy with daily doses of 5 to 1,000 μ g of vitamin B₁₂, serum folic acid activity for *L. casei* may fall sharply and may reach levels below normal before rising again into the normal range. The phenomenon may be due to release of the block in utilization of *L. casei* folic acid activity caused by lack of vitamin B₁₂, with subsequent rapid utilization in hematopoiesis, and may be similar to the fall in serum iron during therapy. Serum folic acid activity for *L. casei* may fall more slowly during specific therapy with smaller (1 μ g) daily doses of vitamin B₁₂.

These findings suggest that in the vitamin B₁₂-deficient subject, PGA is rapidly converted to an *L. casei*-active and presumably metabolically useful form (probably N⁵-methyl-tetrahydrofolic acid) which then "piles up" in the serum because vitamin B₁₂ is required for its normal utilization. This "piled up" folate activity would tend to reduce the amount of folic acid available for other 1-carbon unit transfers. These studies, by providing evidence for the concept that vitamin B₁₂ is required for normal folic acid metabolism, support the possibility that the apparent folic acid deficiency in many patients with vitamin B₁₂ defi-

ciency may be in large measure due to secondarily deranged folic acid metabolism.

Two minor observations of the present study were:

1. The intravenous injection of 15 μ g of PGA per kg of body weight did not appear to affect significantly either the serum vitamin B₁₂ level or the folic acid activity of the red cell for *L. casei*. The latter finding suggests that the mature erythrocyte is relatively impermeable to folic acid.

2. Folic acid activity for *L. casei* and vitamin B₁₂ activity for *E. gracilis* both may be much higher in reticulocyte-rich than in reticulocyte-poor erythrocytes after vitamin B₁₂ therapy. This suggests that the reticulocyte or its precursors, or both are relatively permeable to folic acid and vitamin B₁₂.

ACKNOWLEDGMENT

The authors are indebted to Mrs. Rebecca Fisher Dunn, Mrs. Barbara Bean Mummey, Miss Brenda Conti, and Mrs. Nancy Cunneen Boardman for doing the microbiologic assays, and to Misses Geneva Daland, Carola Kapff, and Louise Jaskiel for obtaining the hematologic data.

REFERENCES

1. Vilter, R. W., Horrigan, D., Mueller, J. F., Jarrold, T., Vilter, C. F., Hawkins, V., and Seaman A. Folic acid, thymine, uracil, and methyl group donors in persons with pernicious anemia and related megaloblastic anemias. *Blood* 1950, 5, 695.
2. Herbert, V. D. *The Megaloblastic Anemias*. New York, Grune & Stratton, 1959.
3. Spray, G. H., and Witts, L. J. The utilization of folic acid given by mouth. *Clin. Sci.* 1952, 11, 273.
4. Girdwood, R. H. A folic-acid excretion test in the investigation of intestinal malabsorption. *Lancet* 1953, 2, 53.
5. Chanarin, I., Mollin, D. L., and Anderson, B. B. The clearance from the plasma of folic acid injected intravenously in normal subjects and patients with megaloblastic anaemia. *Brit. J. Haemat.* 1958, 4, 435.
6. Cox, E. V., Meynell, M. J., Cooke, W. T., and Gaddie, R. Folic acid and cyanocobalamin in pernicious anaemia. *Clin. Sci.* 1958, 17, 693.
7. Herbert, V., and Zalusky, R. Pteroylglutamic acid (PGA) clearance after intravenous injection: Studies using two microbiologic assay organisms. *Clin. Res.* 1961, 9, 161.
8. Herbert, V. The assay and nature of folic acid activity in human serum. *J. clin. Invest.* 1961, 40, 81.
9. Herbert, V. The evaluation of assay methods in folic acid deficiency (abstract). *Blood* 1961, 17, 368.

10. Herbert, V., and Zalusky, R. Vitamin B₁₂ in folic acid metabolism *in* Proc. Fifth Int. Congr. Biochemistry, A. Sissakian, Ed. London, Pergamon Press, 1961.
11. Lear, A. A., Harris, J. W., Castle, W. B., and Fleming, E. M. The serum vitamin B₁₂ concentration in pernicious anemia. *J. Lab. clin. Med.* 1954, **44**, 715.
12. Spray, G. H. An improved method for the rapid estimation of vitamin B₁₂ in serum. *Clin. Sci.* 1955, **14**, 661.
13. Sullivan, L. W., Herbert, V., and Reizenstein, P. In preparation.
14. Zalusky, R., and Herbert, V. Urinary formimino-glutamic acid as test of folic-acid deficiency. *Lancet* 1962, **1**, 108.
15. Knowles, J. P., Pranker, T. A. J., and Westall, R. G. Simplified method for detecting formimino-glutamic acid in urine as a test of folic-acid deficiency. *Lancet* 1960, **2**, 347.
16. Zalusky, R., and Herbert, V. Failure of formimino-glutamic acid (FiGlu) excretion to distinguish vitamin B₁₂ deficiency from nutritional folic acid deficiency (abstract). *J. clin. Invest.* 1961, **40**, 1091.
17. Whipple, G. H., Robscheit-Robbins, F. S., and Bale, W. F. Red cell stroma protein rich in vitamin B₁₂ during active regeneration; anemia studies using radioactive cobalt B₁₂ in dogs. *J. exp. Med.* 1955, **102**, 725.
18. Sullivan, L. W., Herbert, V., and Castle, W. B. Unpublished data.
19. Zalusky, R., and Herbert, V. Megaloblastic anemia in scurvy with response to 50 microgm. of folic acid daily. *New Engl. J. Med.* 1961, **265**, 1033.
20. Hawkins, C. F. Value of serum iron levels in assessing effect of haematinics in the macrocytic anaemias. *Brit. med. J.* 1955, **1**, 383.
21. Herbert, V., Baker, H., Frank, O., Pasher, I., Sobotka, H., and Wasserman, L. R. The measurement of folic acid activity in serum: A diagnostic aid in the differentiation of the megaloblastic anaemias. *Blood* 1960, **15**, 228.
22. Waters, A. H., and Mollin, D. L. Studies on the folic acid activity of human serum. *J. clin. Path.* 1961, **14**, 335.
23. Herbert, V., Larrabee, A. R., and Buchanan, J. M. Studies on the identification of a folate compound of human serum. *J. clin. Invest.* 1962, **41**, 1134.
24. Larrabee, A. R., and Buchanan, J. M. A new intermediate of methionine biosynthesis. *Fed. Proc.* 1961, **20**, 9.
25. Takeyama, S., Hatch, F. T., and Buchanan, J. M. Enzymatic synthesis of the methyl group of methionine. II. Involvement of vitamin B₁₂. *J. biol. Chem.* 1961, **236**, 1102.
26. Larrabee, A. R., Rosenthal, S., Cathou, R. E., and Buchanan, J. M. A methylated derivative of tetrahydrofolate as an intermediate of methionine biosynthesis. *J. Amer. chem. Soc.* 1961, **83**, 4094.
27. Sakami, W., and Uktins, I. Enzymatic methylation of homocysteine by a synthetic tetrahydrofolate derivative. *J. biol. Chem.* 1961, **236**, PC 50.
28. Donaldson, K. O., and Keresztesy, J. C. Further evidence on the nature of prefolic A. *Biochem. biophys. Res. Com.* 1961, **5**, 289.
29. Jaenicke, L. Wirkformen der Folsäure, ihre Struktur und Funktion *in* Second European Symposium on Vitamin B₁₂ and Intrinsic Factor, H. C. Heinrich, Ed. Stuttgart, Enke, 1962, p. 701.
30. Guest, J. R., and Woods, D. D. Metabolic interrelationships between cobalamin and folic acid in the synthesis of methionine by *Escherichia coli* *in* Second European Symposium on Vitamin B₁₂ and Intrinsic Factor, H. C. Heinrich, Ed. Stuttgart, Enke, 1962, p. 686.
31. Kisliuk, R. L. Further studies on the relationship of vitamin B₁₂ to methionine synthesis in extracts of *Escherichia coli*. *J. biol. Chem.* 1961, **236**, 817.
32. Girdwood, R. H. The occurrence of growth factors for *Lactobacillus leichmanii*, *Streptococcus faecalis* and *Leucomostoc citrovorum* in the tissues of pernicious anaemia patients and controls. *Biochem. J.* 1952, **52**, 58.
33. Swendseid, M. E., Bethell, F. H., and Ackermann, W. W. The intracellular distribution of vitamin B₁₂ and folinic acid in mouse liver. *J. biol. Chem.* 1951, **190**, 791.
34. Silverman, M., Law, L. W., and Kaufman, B. The distribution of folic acid activities in lines of leukemic cells of the mouse. *J. biol. Chem.* 1961, **236**, 2530.
35. Romine, M. K. The folic acid activity of human livers as measured with *Lactobacillus casei*. *J. Vitaminol.* 1960, **6**, 196.
36. Dawbarn, M. C., Hine, D. C., and Smith, J. Folic acid activity in the liver of sheep. III. The effect of vitamin B₁₂ deficiency on the concentration of folic acid and citrovorum factor. *Aust. J. exp. Biol. med. Sci.* 1958, **36**, 541.
37. Spray, G. H., and Witts, L. J. Conversion of folic acid to citrovorum factor in health and pernicious anaemia. *Brit. med. J.* 1952, **2**, 62.
38. Will, J. J., Mueller, J. F., Brodine, C., Kiely, C. E., Friedman, B., Hawkins, V. R., Dutra, J., and Vilter, R. W. Folic acid and vitamin B₁₂ in pernicious anemia. Studies on patients treated with these substances over a ten-year period. *J. Lab. clin. Med.* 1959, **53**, 22.
39. Nieweg, H. O., Faber, J. F., De Vries, J. A., and Kroese, W. F. S. The relationship of vitamin B₁₂ and folic acid in megaloblastic anaemias. *J. Lab. clin. Med.* 1954, **44**, 118.
40. Marshall, R. A., and Jandl, J. H. Responses to "physiologic" doses of folic acid in megaloblastic anaemias. *Arch. intern. Med.* 1960, **105**, 352.
41. Zalusky, R., Herbert, V., and Castle, W. B. Cyanocobalamin therapy effect in folic acid deficiency. *Clin. Res.* 1961, **9**, 169; *Arch. intern. Med.* 1962, **109**, 545.

42. Tabor, H., Silverman, M., Mehler, A. H., Daft, F. S., and Bauer, H. L-histidine conversion to a urinary glutamic acid derivative in folic-deficient rats. *J. Amer. chem. Soc.* 1953, **75**, 756.
43. Broquist, H. P., and Luhby, A. L. Detection and isolation of formiminoglutamic acid from urine in folic acid deficiency in humans. *Proc. Soc. exp. Biol. (N. Y.)* 1959, **100**, 349.
44. Rucknagel, D. L., La Du, B. N., Laster, L., Seegmiller, J. E., and Daft, F. S. *quoted in* Silverman, M., and Pitney, A. J. Dietary Methionine and the Excretion of Formiminoglutamic Acid by the Rat. *J. biol. Chem.* 1958, **233**, 1179.
45. Kohn, J., Mollin, D. L., and Rosenbach, L. M. Conventional voltage electrophoresis for formiminoglutamic-acid determination in folic acid deficiency. *J. clin. Path.* 1961, **14**, 345.
46. Silverman, M., Gardiner, R. C., and Bakerman, H. A. The excretion of formiminoglutamic acid by the rat. Influence of dietary ethionine and fat. *Arch. Biochem.* 1960, **87**, 306.
47. Fox, M. R. S., Ludwig, W. J., Barker, H. A., and Weissbach, H. Vitamin B₁₂ activity of 5,6-dimethylbenzimidazolylcobamide coenzyme for the chick. *Proc. Soc. exp. Biol. (N. Y.)* 1960, **105**, 145.
48. Herbert, V. The diagnosis and treatment of folic acid deficiency. *Med. Clin. N. Amer.* In press.
49. Sullivan, L. W., and Herbert, V. Delineation of minimal daily requirement and relative potency of vitamin B₁₂ analogues using minimal dosage therapeutic trials. *Amer. J. clin. Nutr.* 1962, **10**, 354.
50. Noronha, J. M., and Silverman, M. On folic acid, vitamin B₁₂, methionine and formiminoglutamic acid metabolism *in* Second European Symposium on Vitamin B₁₂ and Intrinsic Factor, H. C. Heinrich, Ed. Stuttgart, Enke, 1962, p. 728.
51. Rabinowitz, J. C. Folic acid *in* The Enzymes, 2nd ed., P. D. Boyer, H. Lardy, and K. Myrbäck, Eds. New York, Academic Press, 1960, vol. 2, p. 185.
52. Jukes, T. H., and Broquist, H. P. Biogenesis and metabolism of folic acid and vitamin B₁₂ *in* Metabolic Pathways, D. M. Greenberg, Ed. New York, Academic Press, 1961, vol. II, p. 713.
53. Abrams, R. Nucleic acid metabolism and biosynthesis. *Ann. Rev. Biochem.* 1961, **30**, 165.
54. Beck, W. S. Medical progress: The metabolic functions of vitamin B₁₂. *New Engl. J. Med.* 1962, **266**, 708, 765, 814.
55. Manson, L. A. Vitamin B₁₂ and deoxyribose-synthesis *in* Second European Symposium on Vitamin B₁₂ and Intrinsic Factor, H. C. Heinrich, Ed. Stuttgart, Enke, 1962, p. 191.
56. Wacker, A. Die Biosynthese der Deoxyribose *in* Second European Symposium on Vitamin B₁₂ and Intrinsic Factor, H. C. Heinrich, Ed. Stuttgart, Enke, 1962, p. 196.
57. Lees, F. Radioactive vitamin B₁₂ absorption in the megaloblastic anaemia caused by anticonvulsant drugs. *Quart. J. Med.* 1961, **30**, 231.
58. Herbert, V., and Zalusky, R. Unpublished data.
59. Badenoch, J. The use of labelled vitamin B₁₂ and gastric biopsy in the investigation of anaemia. *Proc. roy. Soc. Med.* 1952, **47**, 426.
60. Hawkins, C. F., and Meynell, M. J. Macrocytosis and macrocytic anaemia caused by anticonvulsant drugs. *Quart. J. Med.* 1958, **27**, 45.
61. Flexner, J. M., and Hartmann, R. C. Megaloblastic anemia associated with anticonvulsant drugs. *Amer. J. Med.* 1960, **28**, 386.
62. Girdwood, R. H. Folic acid, its analogs and antagonists *in* Advances in Clinical Chemistry, H. Sobotka and C. P. Stewart, Eds. New York, Academic Press, 1960, vol. 3, p. 235.
63. Bakerman, H. A. The method for measuring the microbiologic activity of tetrahydrofolic acid and other labile reduced folic acid derivatives. *Analyt. Biochem.* 1961, **2**, 558.